These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 37713090)

  • 1. Population Pharmacokinetics and Exposure-Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1.
    Miao X; Wu LS; Lin SXW; Xu Y; Chen Y; Iwaki Y; Kobos R; Stephenson T; Kemmerer K; Uhlar CM; Banerjee A; Goldberg JD; Trancucci D; Apte A; Verona R; Pei L; Desai R; Hickey K; Su Y; Ouellet D; Samtani MN; Guo Y; Garfall AL; Krishnan A; Usmani SZ; Zhou H; Girgis S
    Target Oncol; 2023 Sep; 18(5):667-684. PubMed ID: 37713090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
    Usmani SZ; Garfall AL; van de Donk NWCJ; Nahi H; San-Miguel JF; Oriol A; Rosinol L; Chari A; Bhutani M; Karlin L; Benboubker L; Pei L; Verona R; Girgis S; Stephenson T; Elsayed Y; Infante J; Goldberg JD; Banerjee A; Mateos MV; Krishnan A
    Lancet; 2021 Aug; 398(10301):665-674. PubMed ID: 34388396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study.
    Nooka AK; Rodriguez C; Mateos MV; Manier S; Chastain K; Banerjee A; Kobos R; Qi K; Verona R; Doyle M; Martin TG; van de Donk NWCJ
    Cancer; 2024 Mar; 130(6):886-900. PubMed ID: 37960969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma.
    Moreau P; van de Donk NWCJ; Delforge M; Einsele H; De Stefano V; Perrot A; Besemer B; Pawlyn C; Karlin L; Manier S; Leleu X; Weisel K; Ghilotti F; Diels J; Elsada A; Morano R; Strulev V; Pei L; Kobos R; Smit J; Slavcev M; Mateos MV
    Adv Ther; 2023 May; 40(5):2412-2425. PubMed ID: 36961654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Teclistamab in Relapsed or Refractory Multiple Myeloma.
    Moreau P; Garfall AL; van de Donk NWCJ; Nahi H; San-Miguel JF; Oriol A; Nooka AK; Martin T; Rosinol L; Chari A; Karlin L; Benboubker L; Mateos MV; Bahlis N; Popat R; Besemer B; Martínez-López J; Sidana S; Delforge M; Pei L; Trancucci D; Verona R; Girgis S; Lin SXW; Olyslager Y; Jaffe M; Uhlar C; Stephenson T; Van Rampelbergh R; Banerjee A; Goldberg JD; Kobos R; Krishnan A; Usmani SZ
    N Engl J Med; 2022 Aug; 387(6):495-505. PubMed ID: 35661166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.
    Moreau P; Mateos MV; Gonzalez Garcia ME; Einsele H; De Stefano V; Karlin L; Lindsey-Hill J; Besemer B; Vincent L; Kirkpatrick S; Delforge M; Perrot A; van de Donk NWCJ; Pawlyn C; Manier S; Leleu X; Martinez-Lopez J; Ghilotti F; Diels J; Morano R; Albrecht C; Strulev V; Haddad I; Pei L; Kobos R; Smit J; Slavcev M; Marshall A; Weisel K
    Adv Ther; 2024 Feb; 41(2):696-715. PubMed ID: 38110653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma.
    Girgis S; Lin SXW; Pillarisetti K; Banerjee A; Stephenson T; Ma X; Shetty S; Yang TY; Hilder BW; Jiao Q; Hanna B; Adams HC; Sun YN; Sharma A; Smit J; Infante JR; Goldberg JD; Elsayed Y
    Target Oncol; 2022 Jul; 17(4):433-439. PubMed ID: 35749004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma.
    Mateos MV; Chari A; Usmani SZ; Goldschmidt H; Weisel K; Qi K; Londhe A; Nair S; Lin X; Pei L; Ammann E; Kobos R; Smit J; Parekh T; Marshall A; Slavcev M; Moreau P
    Clin Lymphoma Myeloma Leuk; 2023 May; 23(5):385-393. PubMed ID: 36967244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma.
    Martin TG; Mateos MV; Nooka A; Banerjee A; Kobos R; Pei L; Qi M; Verona R; Doyle M; Smit J; Sun W; Trancucci D; Uhlar C; van de Donk NWCJ; Rodriguez C
    Cancer; 2023 Jul; 129(13):2035-2046. PubMed ID: 36991547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience.
    Dima D; Davis JA; Ahmed N; Jia X; Sannareddy A; Shaikh H; Shune L; Kaur G; Khouri J; Afrough A; Strouse C; Lochner J; Mahmoudjafari Z; Raza S; Valent J; Anderson LD; Anwer F; Abdallah AO; Hashmi H
    Transplant Cell Ther; 2024 Mar; 30(3):308.e1-308.e13. PubMed ID: 38151105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study.
    Qiu L; Xia Z; Fu C; Chen W; Chang C; Fang B; An G; Wei Y; Cai Z; Gao S; Weng J; Chen L; Jing H; Li F; Liu Z; Chen X; Liu J; Wang A; Yu Y; Xiang W; Lynch K; Yu Z; Fu W
    BMC Med; 2022 Apr; 20(1):108. PubMed ID: 35379237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study.
    Martin TG; Moreau P; Usmani SZ; Garfall A; Mateos MV; San-Miguel JF; Oriol A; Nooka AK; Rosinol L; Chari A; Karlin L; Krishnan A; Bahlis N; Popat R; Besemer B; Martínez-López J; Delforge M; Trancucci D; Pei L; Kobos R; Fastenau J; Gries KS; van de Donk NWCJ
    Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):194-202. PubMed ID: 38052709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study.
    Cortes-Selva D; Perova T; Skerget S; Vishwamitra D; Stein S; Boominathan R; Lau O; Calara-Nielsen K; Davis C; Patel J; Banerjee A; Stephenson T; Uhlar C; Kobos R; Goldberg J; Pei L; Trancucci D; Girgis S; Wang Lin SX; Wu LS; Moreau P; Usmani SZ; Bahlis NJ; van de Donk NWCJ; Verona RI
    Blood; 2024 Aug; 144(6):615-628. PubMed ID: 38657201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world analysis of teclistamab in 123 RRMM patients from Germany.
    Riedhammer C; Bassermann F; Besemer B; Bewarder M; Brunner F; Carpinteiro A; Einsele H; Faltin J; Frenking J; Gezer D; Goldman-Mazur S; Hänel M; Hoegner M; Kortuem KM; Krönke J; Kull M; Leitner T; Mann C; Mecklenbrauck R; Merz M; Morgner A; Nogai A; Raab MS; Teipel R; Wäsch R; Rasche L
    Leukemia; 2024 Feb; 38(2):365-371. PubMed ID: 38245601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma.
    Martin TG; Shah N; Richter J; Vesole DH; Wong SW; Huang CY; Madduri D; Jagannath S; Siegel DS; Biran N; Wolf JL; Parekh S; Cho HJ; Munster P; Richard S; Ziti-Ljajic S; Chari A
    Cancer; 2021 Jun; 127(11):1816-1826. PubMed ID: 33735504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Teclistamab: First Approval.
    Kang C
    Drugs; 2022 Nov; 82(16):1613-1619. PubMed ID: 36352205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma.
    D'Souza A; Shah N; Rodriguez C; Voorhees PM; Weisel K; Bueno OF; Pothacamury RK; Freise KJ; Yue S; Ross JA; Polepally AR; Talati C; Lee S; Jin Z; Buelow B; Vij R; Kumar S
    J Clin Oncol; 2022 Nov; 40(31):3576-3586. PubMed ID: 36029527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma.
    Granger K; Gaffney KJ; Davis JA
    J Oncol Pharm Pract; 2023 Apr; 29(3):722-726. PubMed ID: 36775940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.
    Mateos MV; Nahi H; Legiec W; Grosicki S; Vorobyev V; Spicka I; Hungria V; Korenkova S; Bahlis N; Flogegard M; Bladé J; Moreau P; Kaiser M; Iida S; Laubach J; Magen H; Cavo M; Hulin C; White D; De Stefano V; Clemens PL; Masterson T; Lantz K; O'Rourke L; Heuck C; Qin X; Parasrampuria DA; Yuan Z; Xu S; Qi M; Usmani SZ
    Lancet Haematol; 2020 May; 7(5):e370-e380. PubMed ID: 32213342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma.
    Chari A; Cornell RF; Gasparetto C; Karanes C; Matous JV; Niesvizky R; Lunning M; Usmani SZ; Anderson LD; Chhabra S; Girnius S; Shustik C; Stuart R; Lee Y; Salman Z; Liu E; Valent J
    Hematol Oncol; 2020 Aug; 38(3):353-362. PubMed ID: 32053229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.